Healthcare Private Placement and M&A Transactions Review Week Ending December 18 2022

Alpha 9 Theranostics: The company raised $75 million of Series B venture funding in a deal led by Nextech Invest on December 14, 2022. Longitude Capital, Quark Venture, Samsara BioCapital, Frazier Healthcare Partners, and BVF Partners also participated in the round. The company is an operator of a radiopharmaceutical business intended to improve the diagnosis and treatment of metastatic cancer.

Synchron: The company raised $75 million in Series C venture funding in a deal led by ARCH Venture Partners on December 15, 2022, putting the company’s pre-money valuation at $310 million. Project X, Shanda Group, Khosla Ventures, Gates Family Foundation, Metis Innovative, NeuroTechnology Investors, Forepont Capital Partners, ID8 Investments, Reliance Digital Health, Greenoaks Capital Partners, Alumni Ventures, Moore Strategic Ventures, Bezos Expeditions and The University of Melbourne Endowment also participated in the round. The company is a developer of an implantable brain-computer interface designed to create an endovascular electrode array.

A2 Biotherapeutics: The company raised $71.6 million of Series B venture funding from undisclosed investors on December 16, 2022, putting the company’s pre-money valuation at $390.9 million. The company is a developer of a cell therapy designed to cure cancer via tumor-specific targeting.

Montai Health: The company raised $50 million in Series A venture funding from Flagship Pioneering on December 13, 2022, putting the company’s pre-money valuation at $57 million. The company is a provider of molecular nutrition research to protect and strengthen human health sustainably.

STORM Therapeutics: The company raised GBP 27.9 million of Series B venture funding in a deal led by Fast Track Initiative, Pfizer Ventures, M Ventures, Cambridge Innovation Capital, UTokyo Innovation Platform and Taiho Ventures on December 14, 2022, putting the company’s pre-money valuation at GBP 36.9 million. The company is a developer of small molecule inhibitors of RNA-modifying enzymes designed for the treatment of cancer and other immune diseases.

Peroxitech: The company raised $25 million of Series A venture funding in a deal led by Xontogeny on December 13, 2022, putting the company’s pre-money valuation at $19 million. The company is a developer of a novel drug intended to treat and prevent acute lung injury.

Actuate Therapeutics: The company raised $19.3 million of Series C venture funding from undisclosed investors on December 15, 2022. The company is an operator of a biopharmaceutical business focused on the development of compounds for use in the treatment of cancer, and inflammatory diseases leading to fibrosis.

ActX: The company raised $6.0 million of venture funding from undisclosed investors on December 16, 2022. The company is a provider of actionable genomics services intended to improve health care and personalize medical care through genetics.

Qkine: The company raised GBP 4.3 million of venture funding in a deal led by Parkwalk Advisors and Downing Ventures on December 15, 2022, putting the company’s pre-money valuation at GBP 3.6 million. The company is a manufacturer of high purity, animal-free growth factors, cytokines, and other complex proteins intended to advance stem cell, organoid, and regenerative medicines.

PhenoVista Biosciences: The company raised an undisclosed amount of venture funding from FujiFilm on December 13, 2022. The company is a provider of cell analysis and research services in San Diego, California.

Nimbus Lakshmi / Takeda Pharmaceutical Company: The company reached a definitive agreement to be acquired by Takeda Pharmaceutical Company, a subsidiary of Shanghai Pharmaceuticals, for up to $6 billion on December 13, 2022. The company is a wholly-owned subsidiary of Nimbus Therapeutics, and its tyrosine kinase 2 (TYK2) inhibitor NDI-034858. NDI-034858 is an oral, selective allosteric TYK2 inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.

TXP Pharma / SynAct Pharma: The company was acquired by SynAct Pharma (STO: SYNACT) for an undisclosed amount on December 12, 2022. The company is an operator of a biotech company focused on autoimmune and inflammatory diseases.

Bioasis Technologies / Midatech Pharma: The company reached a definitive agreement to be acquired by Midatech Pharma for CAD 7.4 million on December 13, 2022. Bioasis Technologies Inc is a development stage biopharmaceutical company.

AavantiBio / Solid Biosciences: The company was acquired by Solid Biosciences for an undisclosed amount on December 12, 2022. The company is a developer of a gene therapy for patients with rare genetic diseases.

Bio Elpida / Polyplus-transfection: The company was acquired by Polyplus-transfection, via its financial sponsors ArchiMed, Warburg Pincus and Peugeot Invest, through an LBO on December 14, 2022 for an undisclosed amount. The company is an operator of a contract development and manufacturing company (CDMO) intended to specialize in the development and manufacturing of innovative cell therapies.

Cardialen / Maxwell Biomedical: The company was acquired by Maxwell Biomedical for an undisclosed amount on December 14, 2022. The company is a developer of an atrial fibrillation therapy device designed to restore normal rhythm to help people suffering from heart arrhythmia.

S-Biomedic / Beiersdorf: The company was acquired by Beiersdorf, a subsidiary of Scintia Vermögensverwaltungs, for an undisclosed amount on December 16, 2022. The company is a developer of novel therapeutics intended to establish methods to directly modulate the skin microbiome.